To the Editor In a recent study, Ben-Aharon et al1 showed that only 3 of 10 indications of immune checkpoint inhibitors qualified for tail-of-the-curve bonus points of the American Society of Clinical Oncology Value Framework (ASCO-VF).2 We were puzzled by these counterintuitive findings in light of previous studies using the ASCO-VF and of our experience.3 The authors called for lowering the bar so that more trials could reach thresholds.
Vivot A, Créquit P, Porcher R. Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework. JAMA Oncol. 2018;4(10):1437–1438. doi:10.1001/jamaoncol.2018.3289
Oncology in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.